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Abstract
Background: The methylation status at the human papilloma virus (HPV) genome found in pre-
invasive and invasive cervical lesions suggests that neoplastic transformation can be suppressed by
gene hypermethylation, whereas hypomethylation accompanies or causes cancer progression;
hence, epigenetic therapy aimed at reactivating cellular suppressor-gene expression has the
potential to act as a tumor promoter by enhancing HPV oncoprotein expression in HPV-related
malignancies. The objective of this study was to determine the influence of hydralazine and
valproate on HPV oncogene expression in cervical cancer cell lines and the primary tumors of
patients undergoing treatment with hydralazine and valproate.
Results: Overall, hydralazine and valproate either alone or combined exerted a growth inhibitory
effect on cervical cancer cell lines. A cell line-specific up-regulating effect was observed on E6/E7
gene expression, which in general correlated with DNA hypomethylation and histone acetylation
at the long control region (LCR). Nonetheless, E6/E7 expression was unchanged or decreased in
the majority of patients with cervical cancer treated with hydralazine, valproate, or both. In some
cervical cancer cell lines, these drugs led to increased transcription of p53, and increased its
stabilization due to acetylation at lysines 273 and 282, which allowed a higher bax-protein
transactivating effect.
Conclusion: The results of this study demonstrate that hydralazine and valproate can be safely
administered to HPV-related malignancies such as cervical cancer because they do not increase
viral oncoprotein expression. Most importantly, the antitumor effect of hydralazine and valproate
in cervical cancer may at least partially depend on an up-regulating effect on p53 gene and on the
valproate-induced hyperacetylation of p53 protein, protecting it from degradation by E6.
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Background
Cervical cancer a tumor related to high-risk human papil-
lomavirus (HPV) infection remains as one of the greatest
killers of women worldwide, particularly in underdevel-
oped countries [1]. The realization that viral infections, by
insertion of viral genes into host genomes, can trigger host
defense mechanisms such as methylation machinery acti-
vation has aroused interest in the study of the epigenetic
events occurring in both virus and host genomes [2].
Human genomes harbor DNA sequences resembling ret-
roviral long terminal repeats and the transposable ele-
ments, and indeed there are indications that under certain
situations inappropriate "activation" of these normally
silenced sequences could play a role in the carcinogenic
process [3]. In addition, it has also been established that
some viruses can find ways to adapt different tactics for
regulating expression of their genes through modulation
of DNA methylation; thus, a virus may silence activation
of its genes in a manner that favors establishment of per-
sistent infection and host immune defense evasion [4]. In
addition, viral oncoproteins can possess the ability to
modulate directly or indirectly the methylation machin-
ery in order to silence cellular genes that could interfere
with its tumor-promoting actions, this recently proven by
Burgers et al., who demonstrated that E7 binds and stim-
ulates the enzymatic activity of dnmt1 [5]
One of the first indications of the importance of DNA
methylation and viral gene expression came from studies
of cell transfection with HPV-16 in-vitro  methylated
genomes, demonstrating that under these circumstances
DNA is transcriptionally repressed [6]. SiHa and CasKi
cell lines that harbor HPV-16 and that have a couple of,
and multiple, viral genome copies, respectively, possess a
conserved profile of CpG hypo- and hypermethylation.
Hypermethylation was found in genomic segments over-
lying late genes, while the long control region and the E6
and E7 oncogenes were unmethylated in SiHa cells. Eval-
uation of smears of normal, precursor, and invasive lesion
smears shows that as lesion severity increases, there is pro-
gressive hypomethylation in LCR and E6 gene regions.
These findings led authors to postulate that neoplastic
transformation can be suppressed by gene hypermethyla-
tion, whereas hypomethylation accompanies or causes
cancer progression [7]. Contrariwise, a study performed in
HPV-18 cervical cancer cell lines HeLa and C4-1 and clin-
ical samples found clonal heterogeneity in the methyla-
tion status of the different regions analyzed [8]. A study
focused on the methylation of E2, the early gene that con-
tributes to multiple biological processes including viral
transcription and viral DNA replication, showed that the
ability of E2 protein to bind E2 binding sites (E2BS) in
vitro is inhibited by the methylation of these cytosines [9].
These observations may indicate that the methylation
state of the viral genome, and particularly that of E2BSs,
may vary during the viral life cycle, providing a novel
means for modulating E2 function as infection progresses
[10].
On the other hand, aberrant gene transcription resulting
from epigenetic changes are frequent events in the molec-
ular pathogenesis of malignant transformation. DNA
hypermethylation and histone deacetylation are critical
for determining a closed chromatin structure responsible
for or related with aberrant gene transcription in malig-
nancies [11]. In contraposition to genetic defects, the
reversible nature of epigenetic aberrations constitutes an
attractive therapeutic target; hence, a number of inhibitors
of DNA methylation and histone deacetylases (HDAC)
are at present undergoing pre-clinical testing in combina-
tion for cancer therapy [12-18]. Nevertheless, some
authors argue for caution in the use of epigenetic therapy
for HPV-related malignancies, because it may act as a
tumor promoter by enhancing HPV oncoprotein expres-
sion.
Our group has been interested in the clinical development
of hydralazine and valproate a DNA methylation and his-
tone deacetylases (HDAC) inhibitors respectively as epi-
genetic therapy for cancer including cervical carcinoma
[19-24]. Thus, we wanted to determine the influence of
these drugs on HPV oncogene expression in cervical can-
cer cell lines and on the primary tumors of patients under-
going treatment with hydralazine and valproate.
Results
Growth inhibition by hydralazine and valproate acid in 
cervical cancer cells
As the initial approach to investigate the possible growth-
promoting effect of hydralazine and valproate on HPV-
positive cervical cancer cell lines, SiHa, CasKi, and HeLa
were cultured in the presence of hydralazine, valproate,
and both drugs for 48 h; cell viability was measured at 72
h. As showed in Figure 1, hydralazine exerted an inhibi-
tory effect on HeLa cells and moderate inhibition on SiHa,
and actually had a minor stimulatory effect on CasKi cells;
on the contrary, valproate showed a consistent inhibition
on the three cell lines. This effect was unchanged in SiHa
and HeLa cells with both drugs in combination, whereas
in CasKi the overall effect was inhibitory although less so
than with valproate alone.
E6/E7 gene expression in cervical cancer cell lines
To assess whether these epigenome targeting drugs could
influence viral oncoprotein expression, E6/E7 transcript
expression was assayed by RT-PCR in HPV18-positive
CaLo and HeLa cell lines and in HPV16-positive CasKi
and SiHa cells. As shown in Figure 2a, CaLo cells dis-
played essentially no changes in expression with either
drug or with both drugs in combination as densitometricVirology Journal 2007, 4:18 http://www.virologyj.com/content/4/1/18
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analyses showed a -0.1-fold variation. In HeLa cells, val-
proate induced no changes; however, hydralazine and
hydralazine/valproate up-regulated the transcript 1.17-
and 2.38-fold, respectively. With regard to HPV16 cell
lines, in SiHa cells only the combination of hydralazine/
valproate led to a 0.5-fold increase, while in CasKi,
hydralazine, valproate, and both increased expression by
0.52-, 0.67-, and 0.83-fold, respectively.
Methylation of the LCR in HeLa, and SiHa
To further correlate the transcriptional effect observed
with LCR methylation status, the combined treatment of
hydralazine/valproate was assessed in these cell lines. As
expected, treatment led to a small increase in the intensity
of the bands after digestion with the enzyme McrBC in the
three LCR regions analyzed as compared with untreated
cells, indicating a certain degree of hypomethylation (Fig
2b). These changes – although small – are nonetheless in
line with the slightly higher E6/E7 transcript expression in
these cell lines when treated with these drugs.
H4 acetylation in Calo, CasKy, and HeLa cell lines
To further investigate whether changes in E6/E7 transcrip-
tion are also associated with acetylated H4, chromatin
immunoprecipitation experiments were performed in
these cell lines, amplifying the entire LCR region in three
amplicons: the 5'region; the enhancer region, and the
3'region. In the CaLo cell line, whose E6/E7 expression
did not change with any of the treatments (Figure 1),
acetylated H4 was detected in the three regions analyzed;
however, hydralazine, valproate, and both actually led to
a lower enrichment for acetylated H4, which may explain
the lack of effect of these drugs on E6/E7 expression (Fig-
ure 2c). In line with increased E6/E7 expression in SiHa
(Figure 1), hydralazine, valproate, and the combination
led to an acetylated H4 enrichment at the 5'region of the
LCR, whereas only valproate affected this at the enhancer
region. (Figure 2d).
Expression of E6/E7 in the primary tumors of patients 
treated with hydralazine, valproate, and hydralazine/
valproate
To date, the results in cell lines showed heterogeneous
treatment results with the epigenetic drugs, although in
general these showed correlation between E6/E7 expres-
sion with DNA demethylation and histone hyperacetyla-
tion. To investigate whether these in vitro changes could
also be observed in patients with cervical cancer treated
with these drugs, we analyzed E6/E7 transcript level in the
primary tumors of patients treated in three different clini-
cal trials. Regarding patients treated with hydralazine in a
phase I clinical trial already reported [22], only the pre-
and post-treatment biopsies of two patients whose tumors
harbored HPV16 were available for analysis. As can be
seen in Figure 3a, no changes were observed; nonetheless,
there was no availability of HPV18 samples. Regarding the
valproate trial [24], four pairs of HPV16 and one carrying
HPV18 tumor samples were available for analysis. As
shown in Figure 3b, for the HPV16 samples we observed
no changes at the transcript level in two, a 0.74-fold
increase in one, and a 0.7-fold decrease in another,
Growth inhibition assays in cervical cancer cell lines Figure 1
Growth inhibition assays in cervical cancer cell lines. 
Cells were cultured in the presence of hydralazine, valproate, 
and both drugs for 48 h; cell viability was measured at 72 h. 
Hydralazine exerted an inhibitory effect on HeLa, moderate 
inhibition on SiHa, and a minor stimulatory effect on CasKi 
cells. Valproate showed a consistent inhibition on the three 
cell lines.
a
b
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Expression of E6/E7, methylation at LCR and ChIP assays Figure 2
Expression of E6/E7, methylation at LCR and ChIP assays. 2a. E6/E7 expression was assayed by RT-PCR. CaLo cells no 
changes in expression. In HeLa, hydralazine and hydralazine/valproate up-regulated the transcript 1.17- and 2.38-fold, respec-
tively. In SiHa cells only the combination of hydralazine/valproate led to a 0.5-fold increase, while in CasKi, hydralazine, val-
proate, and both increased expression by 0.52-, 0.67-, and 0.83-fold, respectively. 2b. Hydralazine/valproate led to a small 
increase in the intensity of the bands after digestion with the enzyme McrBC in the three LCR regions analyzed as compared 
with untreated cells, indicating a certain degree of hypomethylation. 3c. ChIP assays with anti acetylated H4. In the CaLo, 
acetylated H4 was detected in the three regions analyzed; hydralazine, valproate, and both decreased the enrichment for 
acetylated H4. In line with increased E6/E7 expression in SiHa had an enrichment of acetylated H4 at the 5' region of the LCR, 
whereas only valproate affected this at the enhancer region.
a
b
c
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whereas in the HPV18 sample expression did not change
(a 0.03-fold decrease). Finally, four cases were able to be
analyzed in patients participating in a phase II trial of
hydralazine and valproate plus cisplatin chemoradiation
(ClinicalTrials.gov Identifier: NCT00404326). In this trial,
17 patients were treated. Hydralazine and valproate were
started 7 days prior to the first application of cisplatin and
radiation, and biopsies were taken at day 7; thus, no con-
founding effect of chemoradiatiation occurred. For this
analysis, only four pairs of samples were available: two
each of HPV16 and -18. As shown in Figure 3c, in one
HPV16 tumor E6/E7 expression diminished (0.63-fold),
whereas the other exhibited no change; expression was
unchanged in both HPV18 samples. Taken together, E6/
E7 expression in primary tumors did not change with
treatment in eight, decreased in two, and increased in one
(two hydralazine, five valproate, and four hydralazine/
valproate) of 11 patients analyzed.
p53 expression
Taken together, these results indicated that the epigenetic
drugs investigated possessed no influence on HPV-early
gene expression by tumor cells in a clinical scenario,
despite the fact that in vitro treatment with these drugs in
some cell lines led to a small increase in expression that
correlated with H4 acetylation and LCR demethylation.
Because we have observed up-regulation of p53 at the
transcriptional level with the combination of hydralazine
and valproate in tumors of patients with breast cancer
[25], and in addition, histone deacetylase inhibitors
acetylate non-histone transcription regulatory proteins
[26], we wanted to analyze whether these epigenetic drugs
would induce changes at p53, which is a key player in
HPV carcinogenesis. For this, we first observed p53 pro-
tein levels by Western blot in CaLo, CasKi, and HeLa cells.
As shown in Figure 4, there was a clear increase of p53 in
CaLo and CasKi cells by hydralazine, valproate, and both,
while in HeLa cells only the combination of hydralazine/
valproate did. To investigate whether the p53 change
occurs at the level of transcription, we analyzed its expres-
sion by RT-PCR. In CaLo, there were no transcriptional
changes; nevertheless, in CasKi p53 expression increased
between 1- and 2-fold, whereas in HeLa the effect was
rather modest, with increased band intensities -0.3-fold.
SiHa cells had p53 increased only by hydralazine and
hydralazine/valproate. It is noteworthy that the transcrip-
tional effect on p53 of hydralazine, valproate, and the
combination in CasKi cells was even higher than that on
the gene DAPK known to be transcriptionally silenced and
reactivated with these drugs in this cell line.
p53 acetylation
To date, these results indicate that changes at p53 occur at
the protein, RNA, or both levels depending on the cell
line. Because acetylation of p53 leads to an increased half-
life that would explain changes observed in Western blots,
we analyzed p53 acetylation by valproate alone and in
combination with hydralazine, using trichostatin A as
positive control. As shown in Figure 5a, immunoprecipi-
tation assays showed that the three drugs or the combina-
tion hyperacetylated p53 at lysine 373 whereas only the
combination of hydralazine-valproate did at lysine 382 in
CaLo cells. Likewise, lysine 373 was hyperacetylated in
Caski by the combination. It is of note that in this cell line,
only TSA acetylated lysine 382. It has already demon-
strated that the binding site of p53 for E6 encompasses the
region containing lysines 372 and 382, and that their
acetylation inhibits p53 ubiquitination induced by E6;
thus, we analyzed this interaction by immunoprecipitat-
ing with E6 antibody and then Western blotted with a p53
antibody. Immunoprecipitates were also probed against
E6 antibody as control. As shown in Figure 5b, despite the
fact that valproate, valproate/hydralazine, and TSA
slightly increased E6 level in these cells, p53 was also
increased. These results indicate that acetylation of p53
protects its degradation by E6. Finally, to assess whether
increased levels of p53 protein was functional, we evalu-
ated in CaLo and CasKi cells the levels of bax protein,
known to be transactivated by p53. As shown in Figure 5c,
hydralazine and valproate in combination led to a strong
increase in bax protein.
Discussion
Currently, epigenetic therapy for malignant neoplasms is
being evaluated in a number of malignancies using DNA
methylation and HDAC inhibitors either alone or in com-
bination with the aim of reactivating the expression of
aberrantly silenced tumor suppressor genes [25,27-29].
Nonetheless, some authors have argued for caution in the
use of epigenetic therapy for HPV-related malignancies as
it may act as a tumor promoter by enhancing HPV onco-
proteins expression. In this study, by analyzing the effect
of the DNA methylation inhibitor hydralazine and the
HDAC inhibitor valproate on cervical cancer cell lines and
primary tumors of patients with cervical cancer treated
with these drugs we demonstrate that although these
drugs in vitro may increase oncoprotein gene expression,
which correlates with demethylation and histone acetyla-
tion, in patients E6 and E7 transcripts are mainly
unchanged. In addition, these drugs may exert a favorable
effect on tumors because cell lines show up-regulation of
p53 expression and acetylation of this protein that is key
in cervical carcinogenesis.
The epigenetic-mediated silencing of cellular genes in cer-
vical cancer is well-established and contributes to malig-
nant progression [30,31]. In HPV carcinogenesis
regulation of E6/E7 expression, the main viral oncogenes
principally depend on viral E2 protein and several cellular
transcription factors such as NF1, AP1, KRF1, Oct1, SP1,Virology Journal 2007, 4:18 http://www.virologyj.com/content/4/1/18
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E6/E7 expression in primary tumors Figure 3
E6/E7 expression in primary tumors. 3a) shows the samples of two patients treated with hydralazine whose transcripts 
were unmodified with the treatment. 3b shows four HPV16 tumors of patients treated with valproate. There were no changes 
in two (1 and 3), a 0.74-fold increase in one (2), and a 0.7-fold decrease in another (4). In the HPV18 sample expression did not 
change. 3c) shows two HPV16 and two HPV18 tumors. A case (1) decreased with treatment while the remaining three had no 
changes.
b
a
cVirology Journal 2007, 4:18 http://www.virologyj.com/content/4/1/18
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and YY1, and the glucocorticoid receptor [32-34]; there-
fore, it is yet unknown to what extent epigenetics contrib-
utes in this regulation. Results of this study reveal that
DNA methylation and histone acetylation possess a heter-
ogeneous participation, because in some cell lines neither
of these inhibitors changed the expression while in others
the methylation inhibitor, the HDAC inhibitor, or both
produced a rather modest transcriptional effect on E6/E7.
Nevertheless, the correlation found between DNA
hypomethylation at three different LCR regions as evalu-
ated by McrBC scanning and H4 hyperacetylation as a
result of the combined treatment with hydralazine and
valproate support that at least in some cervical cancer cell
lines, epigenetic phenomena are active players in E6/E7
oncogene transcriptional regulation. These results are in
agreement with those found in a previous study in which
CasKi cells, known to have the majority of the integrated
HPV DNA copies transcriptionally inactivated, were
treated with the DNA methylation inhibitor 5-azacyti-
dine. The study demonstrates that 5-azacytidine induces
an increase in the intensity of the existing RNA messages
and in the appearance of new transcripts in treated versus
untreated; in contrast, trichostatin A fails to modulate
viral transcription in this cell line [35].
The most important findings, however, comprise those
encountered in the primary tumors of patients treated
with these drugs. As opposed to cell lines, only one of 11
patients had a 0.7-fold increase in HPV16 E6/E7 transcrip-
tion level, whereas there was a decrease in two cases. The
majority (eight of 11), nonetheless, demonstrated no
changes in the transcription of these viral oncogenes. This
finding further underscores the complexity of HPV tran-
scriptional regulation during carcinogenesis. These data
strongly suggest that the epigenetic "status" in cancer cell
lines and tumors are the consequence – rather than the
cause – of the transcriptional activity of E6/E7 oncogenes;
thus, epigenetic therapy agents cannot facilitate increased
viral oncogene activation-driven tumor progression.
In cervical cancer, a number of experimental studies have
consistently shown that although numerous events drive
the malignant conversion of cervical carcinoma cells, E6/
E7 expression appears to be continuously required to
maintain their malignant phenotype [36-38]; in fact,
removing E6 and E7 proteins from HeLa cells via a recom-
binant virus that expresses the bovine papillomavirus E2
protein led to growth inhibition and impaired activation
of p53 and Rb pathways and repression of E2F-responsive
genes inducing growth inhibitory signals to the cells [39].
Because hydralazine and valproate inhibit the growth of
cervical cancer cell lines in studies and did not negatively
affect their E6 and E7 expression, we wanted to investigate
the changes at p53 that plays an important role in HPV
carcinogenesis, on the basis that we had observed up-reg-
ulation of this tumor suppressor gene in patients with
breast cancer on treatment with these drugs [25]. As
shown in Figure 4, these drugs alone or in combination
up-regulated p53 at RNA and protein levels depending on
cell line. A direct transcriptional effect of epigenetic drugs
on p53 has not been clearly demonstrated; however,
demethylation in other genes influencing p53 expression,
such as ASPP1 [40], could explain the results observed.
p53 expression in cell lines Figure 4
p53 expression in cell lines. Western blot (4a) and RT-
PCR (4b) analyses of p53. Hydralazine, valproate and both 
increased p53 in CaLo and CasKi cells whereas only the 
combination did in HeLa cells. CaLo cells showed no tran-
scriptional changes. p53 expression was increased between 
1- and 2-fold in CasKi, whereas on slightly in HeLa. DAPK 
expression was increased as expected with any of these 
treatments.
a
bVirology Journal 2007, 4:18 http://www.virologyj.com/content/4/1/18
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On the other hand, hydralazine by a yet unknown mech-
anism may induce p53 [41], whereas valproic acid and
other HDACs inhibitors also are known to induce p53
gene transcription [42-44]. The extent to which the tran-
scriptional effect on p53 of hydralazine and valproate are
determinant for the growth inhibitory effect observed in
this study is unknown; nonetheless, the strongest influ-
ence on this gene may occur at the protein level as a con-
sequence of valproic acid's acetylating effect at lysines 373
and 382. This is a novel finding regarding valproic acid,
although it could be expected because depsipeptide and
trichostatin A are reported to acetylate these lysines in p53
protein, this acetylation leading to its longer half-life due
to a significant decrease in p53 ubiquitination [45,46]. It
is known that oncogenic human papillomavirus types 16
and 18 utilize this cellular proteolytic system to target the
tumor suppressor protein p53. The HPV E6 oncoprotein
binds to a cellular protein of 100 kd, termed the E6-asso-
ciated protein (E6-AP). The E6-E6-AP complex specifically
interacts with p53, resulting in p53's rapid ubiquitin-
dependent degradation [47,48]. The p53 binding site for
the E6-E6-AP complex encompasses the region containing
lysines 372 and 382; therefore, we analyzed whether
acetylated p53 could be protected from degradation by
E6. As shown in Figure 5, despite the fact that valproate,
valproate/hydralazine, and TSA slightly increased E6 lev-
els, p53 was also increased, indicating that p53 acetyla-
tion protects its degradation by E6 and the expected p53
was functional, as shown by strong transactivation on the
p53-responsive gene bax [49].
Conclusion
The results of this study demonstrate that epigenome-tar-
geting drugs such as hydralazine and valproate used to
reactivate the expression of tumor suppressor genes
silenced by epigenetic aberrations, can be safely adminis-
tered to HPV-related malignancies such as cervical cancer
because these do not induce major changes in the expres-
sion of viral oncoproteins in patients treated with these
drugs, this despite the fact that in at least some cervical
cancer cell lines, hydralazine and valproate may cause a
small up-regulating effect on E6/E7 oncogenes. Most
importantly, the antitumor effect of hydralazine and val-
proate in cervical cancer may at least partially depend on
an up-regulating effect on the p53 gene and in the val-
proate-induced hyperacetylation of p53 protein protect-
ing it from its degradation by E6.
Methods
Cell culture
Cervical cancer cell lines Siha, CasKi, Hela, and Calo were
cultured at 37°C in a humidified atmosphere containing
5% CO2 in DMEM supplemented with 10% (v/v) fetal calf
serum (Life Technologies, Inc.)
DNA extraction and LCR methylation
DNA derived from cell lines was purified with DNeasy Tis-
sue Kit (Qiagen) following protocols suggested by the
supplier. For McrBC digestion (New England Biolabs),
250 ng of DNA was digested with 3 U of enzyme for 1 h
p53 acetylation Figure 5
p53 acetylation. 5a. Immunoprecipitation assays showing 
that the three drugs or the combination hyperacetylated p53 
at lysine 373 whereas only the combination of hydralazine-
valproate did at lysine 382 in CaLo cells. Lysine 373 was 
hyperacetylated in Caski by the combination. 5b. Interaction 
by immunoprecipitation with E6 antibody and then Western 
blotted with a p53 antibody showing an increased p53 indi-
cating that acetylation of p53 protects its degradation by E6. 
5c. Transactivation effect o p53 upon bax protein. Hydrala-
zine and valproate in combination led to a strong increase in 
bax protein.
a
b
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at 37°C in 25 μL of NE buffer 2 (50 mM NaCl, 10 mM
Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitols [pH 7.9]).
Table 1 summarizes the primers employed for LCR meth-
ylation analysis. The PCR mixture contained 1× PCR
buffer, 0.5 U of Taq Gold polymerase, dNTPs (each 1.25
mM), and 0.5 μL of DNA digested with McrBC in a final
volume of 20 μL. Conditions were 95°C for 10 min fol-
lowed by 30 cycles of 95°C for 30 sec, 59°C for 30 sec,
and 72°C for 35 sec, with a final extension cycle of 72°C
for 6 min. The PCR product was separated on a 2% agar-
ose gel, stained with ethidium bromide, and visualized
under ultraviolet (UV) illumination.
Cytotoxicity assays
Cells were seeded into 96-well microtiter Falcon plates
(Becton Dickinson, Franklin Lakes, NJ, USA) at 1.5–2.5 ×
103 cells/well in 0.1 mL of complete medium. The follow-
ing day, cells were treated for 5 days in complete medium
with hydralazine at 10 μM and magnesium valproate at 1
mM. Medium with drugs was changed every other day. At
day 6, cell viability was measured by conventional MTT
dye reduction assay. Briefly, 50 μL of 5 mg/mL MTT rea-
gent in PBS was added to each well. Viable cells with active
mitochondria reduce MTT to an insoluble purple forma-
zan precipitate that is solubilized by the subsequent addi-
tion of 150 μL of DMSO. The formazan dye was measured
spectrophotometrically using an ELISA reader. All assays
were performed in triplicate. The cytotoxic effect of each
treatment was expressed as a percentage of cell viability
relative to untreated control cells (percentage of control)
and is defined as [(A570 nm-treated cells)/A570 nmnon-
treated cells)] × 100.
RNA extraction and expression analysis
Total RNA was obtained from the cell lines treated, or
from frozen biopsies using RNeasy Mini kit (Qiagen)
according to manufacturer instructions. Samples were
treated with 1 U of DNAse I (Gibco-BRL). Amount of RNA
was determined by UV spectrophotometry and quality
was assessed in 2% agarose gels. For cDNA preparation, 1
μg of total RNA was inversely transcribed with random
hexamers using the SuperScript First-strand synthesis sys-
tem for RT-PCR (Invitrogen). The obtained cDNA was
PCR-amplified for E6/E7 expression analysis. For DAPK
gene, primers and PCR conditions used for RT-PCR were
performed as described previously [22].
Western blot
Total cellular proteins were extracted from cells harvested
from a 75-cm2 plate. Cells were pelleted and disrupted
with 300 μL of a lysis buffer (100 mM Tris, pH 8, 100 mM
NaCl, 0.5% Nonidet P-40, 1% apoprotein, 1 mM PMSF).
Proteins were boiled in sample buffer (125 mM Tris-HCL,
pH 6.8, 1% SDS, 2% β-mercaptoethanol, and 0.01%
bromophenol blue) for 5 min and then loaded onto 10–
18% SDS-PAGE. After electrophoresis, proteins were
transferred onto a nitrocellulose Hybond-C extra mem-
brane (Amersham) in a wet chamber during 1 h at 100 V.
Membranes were then blocked with TBS 1× containing
1% skimmed milk and 0.1% Tween-20, washed, and
incubated with the corresponding antibody (E6, p53, Bax,
Actin) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Horseradish peroxidase-conjugated secondary antibody
was used for protein-primary antibody complex detec-
tion. Levels of the corresponding proteins were visualized
using the ECL system (Amersham).
Immunoprecipitation
Cells were harvested and then lysed in lysis buffer (1%
NP-40, 150 mM NaCl, 50 mM Tris, 0.05% SDS, 1 mM
PMSF, and a 1% cocktail of protease inhibitors) on ice for
20 min. After centrifugation at 4°C at 13,000 rpm for 10
min, antibodies (p53 or E6; Santa Cruz Biotechnology)
were added to the supernatant on ice for 1 h. Protein G-
agarose (Santa Cruz Biotechnology) was then added to
the samples, and the samples were rolled at 4°C for 1 h.
After the beads were washed three times with lysis buffer,
the pellets were dissolved into 2 μL of SDS loading buffer
after centrifugation. The protein was analyzed by Western
blotting with different antibodies: anti-E6 (Santa Cruz
Biotechnology) or anti-acetylated p53 (Lys373 and -382;
Upstate).
Table 1: Primers and conditions for amplification.
Primer Set Sense 5' – 3' Antisense 5' – 3' Size, (pb)
HPV16 5' region caccacctcatctacctc caggatgtagcaaatatag 292
HPV16 Enhancer ctatatttgctacatcctg cagcggtatgtaaggc 319
HPV16 3' region gccttacataccgctg gctctgtgcataactgtgg 382
HPV18 5' region cgtgccaggaagtaatatg gatgctgtaaggtgtgcag 301
HPV18 Enhancer ctgcacaccttacagcatc gggtagacagaatgttgg 368
HPV18 3' region ccaacattctgtctaccc gttccgtgcacagatcag 266
HPV16 E6-E7 gggaatccatatgctgtatg gggaagcttttatggtttctgagaacag 597
HPV18 E6-E7 gaatttgcattcaaagatttatttg gggggaattcttactgctgggatgcacacc 673
p53 ctgaggttggctctgactgtaccaccatcc ctcattcagctctcggaacatctcgaagcg 390Virology Journal 2007, 4:18 http://www.virologyj.com/content/4/1/18
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ChIP analysis
Cells were treated with 1% formaldehyde at room temper-
ature for 10 min under constant agitation. The reaction
was stopped by the addition of glycine to a final concen-
tration of 125 mM. Cells were washed twice in ice-cold
PBS 1×, resuspended in lysis buffer (50 mM Hepes-KOH
pH7.9, 10 mM EDTA pH 8.0, 1% SDS) containing pro-
tease inhibitors, and sonicated on ice until crosslinked
chromatin was sheared to an average DNA fragment
length of 0.5–1 kbp. After centrifugation, soluble
crosslinked chromatin was diluted 1:10 in immunopre-
cipitation (IP) buffer (10 mM Hepes-KOH pH 7.9, 1% Tri-
ton X-100, 150 mM NaCl, and protease inhibitors)
divided into aliquots and stored at -70°C. Protein A-Aga-
rose (Upstate) was blocked with BSA (1 mg/mL) and
Salmon-sperm DNA (Sigma-Aldrich) and in IP buffer for
4–6 h at 4°C and subsequently washed extensively with IP
buffer before use. Chromatin preparations were pre-
cleared by incubation with blocked protein A-agarose for
2 h at 4°C. The protein A-agarose was removed by centrif-
ugation; the pre-cleared chromatin was incubated with
antibody (anti acetyl-histone antibody, Upstate) for 12–
14 h at 4°C. Immunoprecipitates were recovered by incu-
bation with fresh blocked protein A-agarose for 2 h at
4°C, followed by low-speed centrifugation. The pellets
were washed three or four times with IP buffer, three times
in wash buffer (10 mM Tris-HCl pH 8.0, 0.25 mM LiCl,
0.5% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA pH
8.0), and three times in Tris-EDTA (TE) pH 8.0. Precipi-
tates were then extracted by incubation with elution
buffer (50 mM Tris pH 8.0, 1% SDS, 50 mM NaHCO3, 1
mM EDTA pH 8.0), and formaldehyde crosslinks were
reversed by treatment with a 1/25 volume of 5 M NaCl for
8 h at 65°C. The DNA was purified by extraction with
phenol and precipitation with ethanol and analyzed by
PCR with primers specific (Table 1). PCR products were
separated on a 2% agarose gel and visualized by ethidium
bromide staining.
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